RxDoctor Payments Data

Mary Szymanski

Nurse Practitioner · Coeur D Alene, IDNPI 1992758585

Payments from drug & device makers

$927in general payments, 2019–2025

Across 34 payments — averaging $27.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$287
  • Abbott$226
  • Boston Scientific$129
  • Pfizer$100
  • Boehringer Ingelheim$49
  • Johnson & Johnson$40
  • plus $97 from 4 others

What the payments were for

  • Food & beverage$927100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$927 in reported general payments places this provider in the 75th percentile of 570 nurse practitioner providers in Idaho.

See all nurse practitioner providers in Idaho

Medicare billing

Part B allowed, 2024
$27,431
Medicare patients
171
Services billed
407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan136$200,301
JardianceEmpagliflozin164$197,604
EliquisApixaban90$95,259
XareltoRivaroxaban36$44,755
Repatha SureclickEvolocumab22$23,923
BrilintaTicagrelor22$16,210
Eplerenone13$2,673
Metoprolol Succinate222$2,572
Potassium Chloride73$2,489
Torsemide153$2,037
Atorvastatin Calcium76$613
Losartan Potassium51$364
Isosorbide Mononitrate ErIsosorbide Mononitrate43$328
Rosuvastatin Calcium19$321
Diltiazem 24hr Er (Cd)Diltiazem Hcl11$275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$287$200,301136 claims
Boehringer IngelheimJardiance$49$197,604164 claims
PfizerEliquis$100$95,25990 claims
Johnson & JohnsonXarelto$40$44,75536 claims
AstraZenecaBrilinta$15$16,21022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 570 nurse practitioner providers in Idaho.

Other nurse practitioner in Coeur D Alene

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →